Losartan/hydrochlorothiazide

From Wikipedia, the free encyclopedia
  (Redirected from Hyzaar)
Jump to navigation Jump to search
Losartan/hydrochlorothiazide
Combination of
LosartanAngiotensin II receptor antagonist
HydrochlorothiazideThiazide diuretic
Clinical data
Trade namesAnzaplus, Cozaar comp, Hyzaar, Ocsaar Plus
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
PubChem CID
KEGG
CompTox Dashboard (EPA)

Losartan/hydrochlorothiazide, sold under the trade name Hyzaar among others, is a combination medication used to treat high blood pressure when losartan is not sufficient.[1] It consists of losartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a diuretic).[1] It is taken by mouth.[1]

Common side effects include dizziness, back pain, and upper respiratory tract infections.[2] Serious side effects may include low blood pressure, kidney problems, allergic reactions, and electrolyte problems.[2] Use in pregnancy and breastfeeding is not recommended.[3] Losartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by decreasing the ability of the kidneys to absorb electrolytes.[2]

The combination was approved for medical use in the United States in 1995.[2] It is avaliable as a generic medication.[1] A month supply in the United Kingdom costs the NHS about 1.50 £ per month as of 2019.[1] In the United States the wholesale cost of this amount is about 2.50 USD.[4] In 2016 it was the 80th most prescribed medication in the United States with more than 9 million prescriptions.[5]

Medical uses[edit]

It is used for high blood pressure (hypertension) once a day. Based on the initial blood pressure response and/or losartan-hydrochlorothiazide side effects, the dosage may be increased or decreased. With each change in dosage, it may take up to a month to see the full effect.

Brand names[edit]

The losartan/hydrochlorothiazide combination preparation is marketed by Merck under the trade name Hyzaar and by Xeno Pharmaceuticals under the name Anzaplus. Merck, Sharp & Dohme market it as Ocsaar Plus in Israel. It is marketed as Cozaar comp in Sweden and South Africa.

References[edit]

  1. ^ a b c d e British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 176. ISBN 9780857113382.
  2. ^ a b c d "Losartan Potassium and Hydrochlorothiazide - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 6 March 2019.
  3. ^ "Hydrochlorothiazide / losartan Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
  4. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
  5. ^ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.